Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Byoung Chul Cho

Showing results (41-50 of 453) with videos related to

Pageof 46
Sort By:
Future Oncology (London, England)|March 9, 2013
Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinomaSun Min Lim, Hye Ryun Kim, Hyo Sup Shim, et al.
Future Oncology (London, England)|August 27, 2024
A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamabAlexander Spira, Nicolas Girard, Matthew Krebs, et al.
Future Oncology (London, England)|August 17, 2023
A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamabAlexander Spira, Nicolas Girard, Matthew Krebs, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 10, 2026
A Response to the Letter to the Editor: "Lazertinib Versus Osimertinib in EGFR-Mutant NSCLC: Efficacy, Toxicity, and Unaddressed Clinical Gaps"Se-Hoon Lee, Shun Lu, James Chih-Hsin Yang, et al.
Cancer Research and Treatment|October 26, 2018
Investigating Trk Protein Expression between Oropharyngeal and Non-oropharyngeal Squamous Cell Carcinoma: Clinical Implications and Possible Roles of Human Papillomavirus InfectionYoon Ah Cho, Ji Myung Chung, Hyunmi Ryu, et al.
Therapeutic Advances in Medical Oncology|May 23, 2024
Multiplex analysis for the identification of plasma protein biomarkers for predicting lung cancer immunotherapy responseMoonki Hong, Sang Wook Lee, Byoung Chul Cho, et al.
Oral Oncology|December 12, 2017
Transoral robotic surgery-based therapy in patients with stage III-IV oropharyngeal squamous cell carcinomaYoung Min Park, Hye Ryun Kim, Byoung Chul Cho, et al.
Therapeutic Advances in Medical Oncology|March 25, 2024
Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancerSu-Jin Choi, Jii Bum Lee, Jae Hwan Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|September 7, 2015
Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cellsJung-Min Choi, Ji-Young Jang, Yu-Ra Choi, et al.
Yonsei Medical Journal|May 25, 2019
Real-World Analysis of the Efficacy of Rebiopsy and <i>EGFR</i> Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung CancerMin Hee Hong, Hye Ryun Kim, Beung Chul Ahn, et al.
Pageof 46

Showing results (41-50 of 453) with videos related to

Sort By:
Pageof 46
Future Oncology (London, England)|March 9, 2013
Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinomaSun Min Lim, Hye Ryun Kim, Hyo Sup Shim, et al.
Future Oncology (London, England)|August 27, 2024
A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamabAlexander Spira, Nicolas Girard, Matthew Krebs, et al.
Future Oncology (London, England)|August 17, 2023
A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamabAlexander Spira, Nicolas Girard, Matthew Krebs, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 10, 2026
A Response to the Letter to the Editor: "Lazertinib Versus Osimertinib in EGFR-Mutant NSCLC: Efficacy, Toxicity, and Unaddressed Clinical Gaps"Se-Hoon Lee, Shun Lu, James Chih-Hsin Yang, et al.
Cancer Research and Treatment|October 26, 2018
Investigating Trk Protein Expression between Oropharyngeal and Non-oropharyngeal Squamous Cell Carcinoma: Clinical Implications and Possible Roles of Human Papillomavirus InfectionYoon Ah Cho, Ji Myung Chung, Hyunmi Ryu, et al.
Therapeutic Advances in Medical Oncology|May 23, 2024
Multiplex analysis for the identification of plasma protein biomarkers for predicting lung cancer immunotherapy responseMoonki Hong, Sang Wook Lee, Byoung Chul Cho, et al.
Oral Oncology|December 12, 2017
Transoral robotic surgery-based therapy in patients with stage III-IV oropharyngeal squamous cell carcinomaYoung Min Park, Hye Ryun Kim, Byoung Chul Cho, et al.
Therapeutic Advances in Medical Oncology|March 25, 2024
Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancerSu-Jin Choi, Jii Bum Lee, Jae Hwan Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|September 7, 2015
Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cellsJung-Min Choi, Ji-Young Jang, Yu-Ra Choi, et al.
Yonsei Medical Journal|May 25, 2019
Real-World Analysis of the Efficacy of Rebiopsy and <i>EGFR</i> Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung CancerMin Hee Hong, Hye Ryun Kim, Beung Chul Ahn, et al.
Pageof 46